

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2022**

**Commission File Number 001-40635**

---

**Reunion Neuroscience Inc.**

(Exact name of Registrant as specified in its charter)

---

N/A

(Translation of Registrant's name)

**30 Duncan Street, Lower North Suite  
Toronto, Ontario  
M5V 2C3  
1-833-833-1967**

(Address and telephone number of registrant's principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

This report on Form 6-K is hereby incorporated by reference into (i) the Registration Statement on Form F-10 (File No. 333-261515) of Reunion Neuroscience Inc. (the “Company”), (ii) the Registration Statement on Form S-8 (File No. 333-268481) of the Company and (iii) the Registration Statement on Form S-8 (File No. 333-260071) of the Company, and in each instance the related prospectus, as such registration statements and prospectuses may be amended or supplemented from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**Financial Statements and Exhibits**

---

**Exhibit**

[99.1](#) [Material Change Report, dated November 28, 2022](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Reunion Neuroscience Inc.**

Date: November 28, 2022

By: /s/ Edward F. Smith

Name: Edward F. Smith

Title: Chief Financial Officer

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1 Name and Address of the Company**

Reunion Neuroscience Inc.  
30 Duncan Street, Lower North Suite  
Toronto, Ontario  
M5V 2C3

**Item 2 Date of Material Change**

November 18, 2022

**Item 3 News Release**

News release with respect to the material change referred to in this Material Change Report was disseminated by the Company through newswire on November 18, 2022, and subsequently filed under the Company's profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at [www.sedar.com](http://www.sedar.com).

**Item 4 Summary of Material Change**

On November 18, 2022, the Company announced that it has entered into an equity distribution agreement dated November 18, 2022 (the "**Distribution Agreement**") with Canaccord Genuity LLC, pursuant to which the Company established an at-the-market equity facility (the "**ATM Facility**").

**Item 5 Full Description of Material Change**

Pursuant to the ATM Facility, the Company may, at its discretion sell up to US\$10,000,000 of its common shares through "at-the-market" issuances on the Nasdaq Stock Market in the United States. No common shares will be offered or sold on the Toronto Stock Exchange or any other marketplace in Canada. The Company intends to use the net proceeds from the ATM Facility, if any, principally for general corporate purposes to fund ongoing operations.

The offer and sale of the common shares under the ATM Facility will be made by means of a prospectus supplement dated November 18, 2022 (the "**Prospectus Supplement**") which supplements the Company's existing short form base shelf prospectus dated December 3, 2021 (the "**Base Shelf Prospectus**") included in the Company's U.S. registration statement on Form F-10 (File No. 333-261515) under the U.S.-Canada multijurisdictional disclosure system (the "**Registration Statement**"). Copies of the Registration Statement and the Prospectus Supplement can be found on EDGAR at [www.sec.gov](http://www.sec.gov) and copies of the Base Shelf Prospectus and the Prospectus Supplement can be found on SEDAR at [www.sedar.com](http://www.sedar.com). Copies of such documents may also be obtained from Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, 12th Floor, Boston MA 02190, by email at [prospectus@cgf.com](mailto:prospectus@cgf.com).

**Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7 Omitted Information**

Not applicable.

---

**Item 8**      **Executive Officer**

The following senior officer of the Company is knowledgeable about the material change and this material change report, and may be contacted as follows:

Curtis Weber, General Counsel & Corporate Secretary  
Telephone: 1 (888) 880-7386  
Email: [investors@reunionneuro.com](mailto:investors@reunionneuro.com)

**Item 9**      **Date of Report**

November 28, 2022

---